Editas Medicine, Inc. (EDIT)
|Net Income (ttm)||-166.66M|
|Day's Range||59.75 - 61.47|
|52-Week Range||27.01 - 99.95|
|Price Target||53.92 (-12.1%)|
|Est. Earnings Date||Nov 4, 2021|
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is... [Read more...]
In 2020, EDIT's revenue was $90.73 million, an increase of 341.93% compared to the previous year's $20.53 million. Losses were -$115.98 million, -13.29% less than in 2019.Financial Statements
According to 12 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price forecast is 53.92, which is a decrease of -12.05% from the latest price.
Wood is following an important strategy with gene-editing stocks.
Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared fi...
Final Trades: Stryker, Editas Medicine, Oracle & more
The "Halftime Report" traders give their top picks to watch for the second half.
Initial Clinical Data from Editas Medicine's BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the I...
Data to include patient safety assessments and a preliminary analysis of secondary endpoints to evaluate biological activity
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. The post Forget About the Genomic Rev...
Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology. The post Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and ...
Editas Medicine Inc (NASDAQ: EDIT) announced data on a new gene-editing technology termed SLEEK (SeLection by Essential-gene Exon Knock-in). Data were presented at the Cold Spring Harbor Laboratory's G...
Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory's Genome Engineer...
SLEEK enables high efficiency, multi-transgene knock-in of induced Pluripotent Stem Cells (iPSCs), T cells, and Natural Killer (NK) cells
Editas' (EDIT) lead candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating hematologic diseases.
Our indicative theme of Gene Editing stocks has returned about 11% year-to-date, compared to the S&P 500 which is up by about 19% over the same period. However, the gains have overwhelmingly come from a...
Editas could be an attractive acquisition candidate for the big vaccine maker.
The stock price of Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has seen a rise of over 20% over the last twenty-one trading days, and it is a...
Another analyst ups his recommendation on the stock.
With the trading day more than halfway over, the broad markets were fairly mixed. While the Dow Jones industrial average and S&P 500 had pulled back slightly from their all-time highs, they still seem p...
Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. The post Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are C...
Editas (EDIT) reports narrower-than-expected loss in the second quarter of 2021 while revenues miss estimates. Focus remains on the development of CRISPR gene-editing candidate, EDIT-101.
Thursday Afternoon Analyst Upgrades and Downgrades: Bath & Body Works, Editas, GoDaddy, PetMed, Qorvo and More
With the trading day about halfway over, S&P 500, Nasdaq and Dow Jones industrial average were pushing higher for a number of reasons.
Editas (EDIT) delivered earnings and revenue surprises of 4.71% and -94.33%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Enrolling first pediatric and adult high dose cohorts of EDIT-101 BRILLIANCE trial for LCA10
On Editas' (EDIT) second-quarter earnings call, investor focus will likely be on the company's progress with the development of EDIT-101, its lead pipeline candidate.
In the latest trading session, Editas Medicine (EDIT) closed at $41.86, marking a -0.1% move from the previous day.